FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOUS INJECTION IN THE TREATMENT OF HER2-POSITIVE BREAST CANCER (HER2+BC) PATIENTS IN ITALY: A BUDGET IMPACT ANALYSIS

被引：0
|
作者：
Bellone, M. [1 ]
Pradelli, L. [1 ]
Sanfilippo, A. [1 ]
Caputo, A. [2 ]
Manevy, M. [3 ]
Zerilli, A. [4 ]
机构：
[1] AdRes HEOR, Turin, TO, Italy
[2] Roche Spa, Monza, Italy
[3] F Hoffmann La Roche Ltd, Delemont, Switzerland
[4] Roche Spa, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSC113
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [21] BUDGET IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER IN SPECIALTIES HOSPITAL IN ECUADOR
    Irigoyen, P.
    Moreno, A.
    Gavilanes, C.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [22] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+Breast Cancer Patients
    Munzone, Elisabetta
    Fabi, Alessandra
    Buono, Giuseppe
    Caputo, Roberta
    Montagna, Emilia
    Negri, Mara
    Nuzzo, Francesco
    Palazzo, Antonella
    Paris, Ida
    Conti, Luca
    Baggi, Anna
    Franzini, Jean Marie
    De Laurentiis, Michelino
    DRUGS & THERAPY PERSPECTIVES, 2023, 39 (12) : 432 - 446
  • [23] The PHASTER Study: Economic and Organizational Impact of Subcutaneous (SC) Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Treatment of HER2+ Breast Cancer Patients
    Elisabetta Munzone
    Alessandra Fabi
    Giuseppe Buono
    Roberta Caputo
    Emilia Montagna
    Mara Negri
    Francesco Nuzzo
    Antonella Palazzo
    Ida Paris
    Luca Conti
    Anna Baggi
    Jean Marie Franzini
    Michelino De Laurentiis
    Drugs & Therapy Perspectives, 2023, 39 : 432 - 446
  • [24] Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    Swain, Sandra M.
    Baselga, Jose
    Kim, Sung-Bae
    Ro, Jungsil
    Semiglazov, Vladimir
    Campone, Mario
    Ciruelos, Eva
    Ferrero, Jean-Marc
    Schneeweiss, Andreas
    Heeson, Sarah
    Clark, Emma
    Ross, Graham
    Benyunes, Mark C.
    Cortes, Javier
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 724 - 734
  • [25] Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    Douchet, G.
    Richard, Sandrine
    ONCOLOGIE, 2018, 20 (01) : 43 - 44
  • [26] Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
    von Minckwitz, Gunter
    Procter, Marion
    de Azambuja, Evandro
    Zardavas, Dimitrios
    Benyunes, Mark
    Viale, Giuseppe
    Suter, Thomas
    Arahmani, Amal
    Rouchet, Nathalie
    Clark, Emma
    Knott, Adam
    Lang, Istvan
    Levy, Christelle
    Yardley, Denise A.
    Bines, Jose
    Gelber, Richard D.
    Piccart, Martine
    Baselga, Jose
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (02): : 122 - 131
  • [27] Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer
    Melichar, Bohuslav
    Studentova, Hana
    Kalabova, Hana
    Vitaskova, Denisa
    IMMUNOTHERAPY, 2014, 6 (07) : 811 - 819
  • [28] Handling of anti-HER2 antibodies, trastuzumab and pertuzumab, in patients with HER2-positive breast cancer
    Araki, Kazuhiro
    Ito, Yoshinori
    ANNALS OF ONCOLOGY, 2015, 26 : 48 - 48
  • [29] HOSPITAL CAPACITY TOOL TO ASSESS THE POTENTIAL IMPACT OF USING A FIXED DOSE COMBINATION OF PERTUZUMAB/TRASTUZUMAB FOR SUBCUTANEOUS INJECTION VERSUS INTRAVENOUS PERTUZUMAB/ TRASTUZUMAB IN HER2+BREAST CANCER
    Cunha, A.
    VALUE IN HEALTH, 2023, 26 (12) : S296 - S296
  • [30] Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer
    De Sanctis, R.
    D'Antonio, F.
    Agostinetto, E.
    Marinello, A.
    Masci, G.
    Zuradelli, M.
    Losurdo, A.
    Guiducci, D.
    Tinterri, C.
    Testori, A.
    Gatzemeier, W.
    Errico, V.
    Torrisi, R.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 71 - 71
12345